Would the Trump administration's recently proposed drug pricing reforms hurt the biotech sector more than pharma? Seeking ...

The EO states that while American citizens represent only 5% of the global population, they fund around 75% of global ...

Pharmaceutical tariffs, as proposed by President Donald Trump, aim to create manufacturing jobs in the United States, limit ...

Lowering drug prices to European benchmarks would ultimately reduce innovation and cost American consumers just over half a ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

Toward the end of his first Administration, Trump signed a similar Executive Order aimed at lowering the prices of some drugs ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Eli Lilly and Co. and Purdue University announced Friday that Lilly will invest $250 million in a collaboration between the two over the next eight years. Lilly’s investment is intended to accelerate ...

The package revives President Donald Trump’s much-maligned Most Favored Nation rule but goes further into the private markets and beyond, leveraging the patent system, drug importation and more.

Trump tried to implement a similar rule at the end of his last term in 2020. However, it was squashed by federal courts for procedural reasons. The latest executive order will also likely be ...